 |
 |
To locate an attorney to
evaluate your case, choose
from a practice area below:
|
|
|
|
|
|
Hormone Replacement Therapy
HRT Health Risks - Breast Cancer
Invasive (Infiltrating) Lobular Breast Cancer
One of the more recent studies of the association between invasive (infiltrating) lobular breast cancer and hormone replacement therapy was published in the June 2004 issue of Cancer. The study, conducted by a team of researchers headed by A. Tjonneland, demonstrated a 3.53 times increase in the relative risk of developing invasive (infiltrating) lobular breast cancer associated with the use of hormone replacement therapy. The data also demonstrated a 2.10 times increase in the relative risk of developing ductal breast cancer associated with the use of hormone replacement therapy. The data also suggested that the continuous use of progestin hormone replacement therapy was associated with an increased risk of developing invasive (infiltrating) lobular breast cancer as well as ductal breast cancer. Example of such continuous therapy include regimens that consist of both single hormone replacement therapy - such as Provera® and generic medroxyprogesterone acetate (MPA) - and combination hormone replacement therapy - such as Prempro®, Premphase® and FemHRT®.
Another recent study, published in the June 25, 2003 issue of the Journal of the American Medical Association demonstrated an increased risk of developing both invasive (infiltrating) lobular breast cancer and ductal breast cancer among women who used combined estrogen and progestin hormone replacement therapy. The risk of developing either invasive (infiltrating) lobular breast cancer or ductal breast cancer increased with the duration of hormone therapy. For those using combined estrogen and progestin hormone replacement therapy, such as that provided by drugs like Prempro®, Premphase® and FemHRT®, for 5-15 years, there was a 3.7-fold increase in the risk of developing invasive (infiltrating) lobular breast cancer and a 1.5-fold increase in the risk of developing ductal breast cancer. For those using combined estrogen and progestin hormone replacement therapy, such as that provided by drugs like Prempro®, Premphase® and FemHRT®, for over15 years, there was a 2.6-fold increase in the risk of developing invasive (infiltrating) lobular breast cancer and a 1.6-fold increase in the risk of developing ductal breast cancer.
If you or a loved one have developed invasive lobular breast cancer or ductal breast cancer after using hormone replacement drugs such as Prempro®, Provera®, Premphase®, FemHRT® or the generic medroxyprogesterone acetate (MPA) and would like to learn more about your legal rights, please click here.
Please click here if you or a loved one used Hormone Replacement Therapy (HRT) medications and suffer from:
|
Breast Cancer |
Ovarian Cancer |
| Non-Hodgkin's Lymphoma |
Gall Bladder Cancer |
Choose the state where you live to locate a
Hormone Replacement Therapy lawyer near you.
|
|
|
